Lexicon Pharmaceuticals Statistics
Total Valuation
LXRX has a market cap or net worth of $660.94 million. The enterprise value is $626.95 million.
Important Dates
The last earnings date was Thursday, March 5, 2026, before market open.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LXRX has 423.68 million shares outstanding. The number of shares has increased by 13.44% in one year.
| Current Share Class | 423.68M |
| Shares Outstanding | 423.68M |
| Shares Change (YoY) | +13.44% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 1.39% |
| Owned by Institutions (%) | 21.80% |
| Float | 417.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.27 |
| Forward PS | 25.36 |
| PB Ratio | 5.27 |
| P/TBV Ratio | 10.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 12.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.88, with a Debt / Equity ratio of 0.58.
| Current Ratio | 4.88 |
| Quick Ratio | 4.73 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.87 |
Financial Efficiency
Return on equity (ROE) is -39.72% and return on invested capital (ROIC) is -14.49%.
| Return on Equity (ROE) | -39.72% |
| Return on Assets (ROA) | -12.65% |
| Return on Invested Capital (ROIC) | -14.49% |
| Return on Capital Employed (ROCE) | -29.80% |
| Weighted Average Cost of Capital (WACC) | 9.87% |
| Revenue Per Employee | $614,852 |
| Profits Per Employee | -$621,494 |
| Employee Count | 81 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 25.64 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +305.93% in the last 52 weeks. The beta is 1.01, so LXRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +305.93% |
| 50-Day Moving Average | 1.44 |
| 200-Day Moving Average | 1.25 |
| Relative Strength Index (RSI) | 50.95 |
| Average Volume (20 Days) | 2,612,570 |
Short Selling Information
The latest short interest is 23.14 million, so 5.46% of the outstanding shares have been sold short.
| Short Interest | 23.14M |
| Short Previous Month | 24.52M |
| Short % of Shares Out | 5.46% |
| Short % of Float | 5.54% |
| Short Ratio (days to cover) | 7.50 |
Income Statement
In the last 12 months, LXRX had revenue of $49.80 million and -$50.34 million in losses. Loss per share was -$0.14.
| Revenue | 49.80M |
| Gross Profit | 43.24M |
| Operating Income | -48.91M |
| Pretax Income | -50.34M |
| Net Income | -50.34M |
| EBITDA | -48.29M |
| EBIT | -48.91M |
| Loss Per Share | -$0.14 |
Full Income StatementBalance Sheet
The company has $96.23 million in cash and $62.24 million in debt, with a net cash position of $33.99 million or $0.08 per share.
| Cash & Cash Equivalents | 96.23M |
| Total Debt | 62.24M |
| Net Cash | 33.99M |
| Net Cash Per Share | $0.08 |
| Equity (Book Value) | 107.54M |
| Book Value Per Share | 0.30 |
| Working Capital | 81.03M |
Full Balance SheetCash Flow
| Operating Cash Flow | -67.85M |
| Capital Expenditures | n/a |
| Free Cash Flow | -67.85M |
| FCF Per Share | -$0.16 |
Full Cash Flow StatementMargins
Gross margin is 86.82%, with operating and profit margins of -98.21% and -101.08%.
| Gross Margin | 86.82% |
| Operating Margin | -98.21% |
| Pretax Margin | -101.08% |
| Profit Margin | -101.08% |
| EBITDA Margin | -96.96% |
| EBIT Margin | -98.21% |
| FCF Margin | n/a |
Dividends & Yields
LXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.44% |
| Shareholder Yield | -13.44% |
| Earnings Yield | -7.62% |
| FCF Yield | -10.27% |
Analyst Forecast
The average price target for LXRX is $4.15, which is 166.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.15 |
| Price Target Difference | 166.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 31.57% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 21, 2015. It was a reverse split with a ratio of 1:7.
| Last Split Date | May 21, 2015 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
LXRX has an Altman Z-Score of -12.66 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.66 |
| Piotroski F-Score | 3 |
